Clinical trials
-
Upload
waseem-rather -
Category
Health & Medicine
-
view
14 -
download
0
Transcript of Clinical trials
![Page 1: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/1.jpg)
Presented by: Rather waseem yousuf
![Page 2: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/2.jpg)
Clinical TrialsA clinical trial : prospectively planned
experiment for the purpose of evaluating potentially beneficial therapies or treatments
In general, these studies are conducted under as many controlled conditions as possible so that they provide definitive answers to pre-determined, well-defined questions
![Page 3: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/3.jpg)
Why Clinical Trials?1. Most definitive method to determine
whether a treatment is effective.
Other designs have more potential biases
One cannot determine in an uncontrolled setting whether an intervention has made a difference in the outcome.
![Page 4: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/4.jpg)
Why Clinical Trials?2. Help determine incidence of side effects and
complications.
3. Theory not always best path
![Page 5: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/5.jpg)
TYPES3 ways of classificationResearchers behavior Clinical observational study Interventional study
Purpose based Prevention trials Screening trials Diagnostic trials Treatment trials Supportive care trials
![Page 6: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/6.jpg)
TYPES
Weather trial design allow changes based on data accumulated
Fixed trialAdaptive clinical trial
Miscellaneous typesField trialsCommunity trials
![Page 7: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/7.jpg)
Phases of Clinical TrialPhases of Clinical Trial
![Page 8: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/8.jpg)
Phase 0Phase 0Also called Human Micro-dosing studies.
Gathers preliminary data Pharmacodynamics and Pharmacokinetics.
Gives no data on safety or efficacy.
Small number of subjects (10-15).
![Page 9: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/9.jpg)
Phase IPhase IFirst stage of testing in human subjects (20-100).
Designed to assess the safety, tolerability, PK and PD of drug.
Dose ranging – Dose escalation.
![Page 10: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/10.jpg)
Phase IIPhase IITherapeutic Exploratory Trial. (20-300 Subjects).
Efficacy in patients (primary objective)
Safety issues (secondary objective)
Optimum dose finding
![Page 11: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/11.jpg)
Phase IIIPhase III
Therapeutic confirmatory trials. (300-3000 subjects).
To establish efficacy of the drug against existing therapy in larger number of patients, method of usage etc.,.
![Page 12: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/12.jpg)
Phase IVPhase IVPost Marketing Studies (PMS).
Involves safety surveillance.
Determine behavior of drug in real life situations.
Evaluate action of drug in a situation of missed dosage or over dosage.
![Page 13: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/13.jpg)
CLINICAL TRIAL PROTOCOLDefines and manages trialRequired by the regulatory organizationsPrepared by panel of expertsProvides background about the trialSpecifies trial objectivesDescribes trial design Ensures that trial procedures are consistently
carried out
![Page 14: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/14.jpg)
COMPONENTS
1. General information Title of trial Names and adresses of investigators and
sponsors Identity of trial site
2. Justification and objectives Reason for execution of trial Primary hypothesis to be tested Primary end point
![Page 15: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/15.jpg)
COMPONENTS3. Design Response variables (nature of response variable , scoring system) Efficacy (magnitude of difference to be detected between treatment and
control groups)4. Duration Date of beginning Date of end Duration of disease under study Duration of treatment Drug withdrawal period Decision rules for terminating a trial
![Page 16: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/16.jpg)
COMPONENTS5. Experimental population
Population in which trial is conducted Should be representative of target population
Experimental unit (smallest independent unit to which treatment is randomly
allocated) Composition (e.g. Age , sex , breed) Inclusion/exclusion criteria Selection of controls (to allow discrimination of patient
outcomes caused by other factors , fair comparisons)
![Page 17: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/17.jpg)
COMPONENTS Sample size determination
• Level of significance• Power
Owners informed consent6.Therapeutic or prophylactic procedure Dosage Product formulation and identification Placebo/standard treatment formulation and identification Method of administration Operators safety
![Page 18: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/18.jpg)
Bias and VariabilityThe clinical trial is considered to be the “gold standard” in
clinical research
Clinical trials provide the ability to reduce bias and variability that can obscure the true effects of treatment
Bias affects accuracy
Variability affects precision
![Page 19: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/19.jpg)
Bias: any influence which acts to make the observed results non-representative of the true effect of therapy
Examples:
healthier patients given treatment A, sicker patients given treatment B
treatment A is “new and exciting” so both the physician and the patient expect better results on A
![Page 20: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/20.jpg)
Variability: high variability makes it more difficult to discern treatment differences
Some sources of variabilityMeasurement
instrument Observer
Biologic within individuals between individuals
![Page 21: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/21.jpg)
Fundamental principle in comparing treatment groups:Groups must be alike in all important aspects and only
differ in the treatment each group receives
In practical terms, “comparable treatment groups” means “alike on the average”
![Page 22: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/22.jpg)
Why is this important?If there is a group imbalance for an important factor
then an observed treatment difference may be due to the imbalance rather than the effect of treatment
Example:Drug X versus placebo for osteoporosisAge is a risk factor for osteoporosisOlder subjects are enrolled in Drug X groupTreatment group comparison will be biased due to
imbalance on age
![Page 23: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/23.jpg)
How can we ensure comparability of treatment groups?We can not ensure comparability but randomization helps
to balance all factors between treatment groups
If randomization “works” then groups will be similar in all aspects except for the treatment received
![Page 24: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/24.jpg)
RandomizationAllocation of treatments to participants is carried out
using a chance mechanism so that neither the patient nor the physician know in advance which therapy will be assigned
Simplest Case: each patient has the same chance of receiving any of the treatments under study
![Page 25: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/25.jpg)
Randomization
![Page 26: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/26.jpg)
Simple Randomization
Think of tossing a coin each time a subject is eligible to be randomized HEADS: Treatment A TAILS: Treatment B
Approximately ½ will be assigned to treatments A and B
![Page 27: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/27.jpg)
Problem with Simple Randomization:May result in substantial imbalance in either
an important baseline factor and/orthe number of subjects assigned to each group
Solution: Use blocking and/or stratified randomization
![Page 28: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/28.jpg)
Block RandomizationArranging experimental units in groups that are
similar to one another
Typically , blocking factor is source of variability that is not of primary interest to the experimenter
![Page 29: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/29.jpg)
The Randomized Block Design Divides the group of experimental units into n
homogeneous groups of size t These homogeneous groups are called blocks The treatments are then randomly assigned to the
experimental units in each block - one treatment to a unit in each block
![Page 30: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/30.jpg)
Stratification ExampleTo ensure balance on an important baseline factor,
create strata and set up separate randomization schedules within each stratum
Example: if we want prevent an imbalance on age in an osteoporosis study, first create the strata “< 75 years” and “ 75 years”
then randomize within each stratum separatelyBlocking should be also be used within each stratum
![Page 31: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/31.jpg)
Stratification
![Page 32: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/32.jpg)
BlindingMasking the identity of the assigned interventions
Main goal: avoid potential bias caused by conscious or subconscious factors
Single blind: patient is blinded
Double blind: patient and assessing investigator are blinded
Triple blind: committee monitoring response variables (e.g.
statistician) is also blinded
![Page 33: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/33.jpg)
How to Blind
To “blind” patients, can use a placebo
Examples
pill of same size, color, shape as treatment
sham surgery
sham device such as sham acupuncture
![Page 34: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/34.jpg)
General Study DesignsParallel group designs Type of clinical design which compares two
treatments (A and B) so that one group receives only A while
other group receives only B
R A N D
A
B
C
control
![Page 35: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/35.jpg)
Cross-Over DesignsSubjects are randomized to sequences of treatments
(A then B or B then A)
Uses the patient as his/her own control
Often a “wash-out” period (time between treatment periods) is used to avoid a “carry over” effect (the effect of treatment in the first period affecting outcomes in the second period)
Can have a cross-over design with more than 2 periods
![Page 36: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/36.jpg)
General Study DesignsCross-Over Designs
R A N D
A
B
B
A
WASH-OUT
![Page 37: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/37.jpg)
Cross-Over Designs
Advantage: treatment comparison is only subject to within-subject variability not between-subject variability
reduced sample sizes
Disadvantages:strict assumption about carry-over effectsinappropriate for certain acute diseases (where a
condition may be cured during the first period)drop outs before second period
![Page 38: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/38.jpg)
General study designsSequential trials It is one whose conduct at any stage depends
on the results so far obtained
Two treatments are compared , experimental units enter the trial in pairs
Results are analyzed sequentially according to the outcome in the pairs
![Page 39: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/39.jpg)
Sequential Design
Continue to randomize subjects until H0 is either rejected or “accepted”
A large statistical literature for classical sequential designs
Developed for industrial setting
![Page 40: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/40.jpg)
General study designsAdvantages:1.Early detection of beneficial treatment effects
2. Require fewer experimental units
3. Significance tests can be conducted repeatedly on accumulating data
![Page 41: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/41.jpg)
General study designsDisadvantages:
1.Difficult to plan
2.Unsuited to the trial in which treatment response times are long
![Page 42: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/42.jpg)
Losses to “follow-up”It refers to subjects who at one point in time
were actively participating in a clinical trial ,but have become lost at the point of follow-up in trial
Reasons:• Withdrawal from the trial without informing
investigator• Moved away from the trial site• Became ill and unable to communicate
![Page 43: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/43.jpg)
Compliance Success of a trial depends on participants acting
in accordance with the instructions of the trial designers; that is, complying with treatment
Reasons for poor compliance 1.Unclear instructions2.Forgetfulness3.Inconvenience of participation4.Disappointment with results5.Side effects
![Page 44: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/44.jpg)
Terminating a trial It may be necessary to terminate a trial
prematurely if there are serious adverse side effects in the treatment group, and such a decision rule should be written into the trial’s protocol
![Page 45: Clinical trials](https://reader035.fdocuments.in/reader035/viewer/2022070520/58f9b1721a28abc3328b4621/html5/thumbnails/45.jpg)